Here is the Google Doc for the full report and better experience: https://docs.google.com/document/d/191C_pNtCkEXcJoXj37nlQ_ejiiW6x1bJaOT67oRnyBM/edit?usp=sharing
Bionano Genomics, Inc!.
101% DUE DILIGENCE
The Structural Variation Company
Frunkla Investment (Dayo Nurudeen)
THIS IS NOT FINANCIAL ADVICE. THIS IS FOR FUN PURPOSE ONLY
INTRODUCTION TO BIONANO GENOMICS
Bionano Genomics, Inc. is a structural variation (See Fig.2) company that uses optical genome mapping technology to analyze genomes of living things such as plants, humans, or animals.
Fig.2: Types of Structural Variations that can be detected by Saphyr
Bionano Genomics is committed to unlocking understanding of genome (See Fig.3) biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering, and genome discovery.
Fig.3: Cell*/Chromosome/DNA/Gene/*Base Pairs
Genomics is defined as the study of genes and their functions, and related techniques.
Gaining a better understanding of the interactions between genes and the environment by means of genomics is helping researchers find better ways to improve health and prevent disease.
According to Princeton University on Thursday, June 21, 2018 “BioNano Genomics’ technology offers a large-scale view of the DNA molecule, letting researchers see where genes are located relative to each other. The technology also could potentially reveal other elements such as open reading frames, noncoding frames, repetitive regions and even epigenomic patterns. This information is often destroyed when DNA is cut up for use in traditional sequencers. The technology also can reveal sites of DNA damage, mutations and structural variations such as duplications, deletions, and extra copies of genes.
Current sequencing techniques are limited to short segments of DNA, requiring researchers to piece together the segments in a manner not unlike putting together a jigsaw puzzle. Yet researchers would like to examine sequences of whole sets of genes and other long segments of non-coding regions of the genome.
The technology was developed at Princeton by a multidisciplinary collaboration among faculty from the School of Engineering and Applied Science, the Department of Physics, and the Department of Molecular Biology. It was supported by a grant from the Defense Advanced Research Projects Agency. The inventors were: Cao; Steven Chou, Joseph C. Elgin Professor of Engineering; Robert Austin, professor of physics; and former postdoctoral fellow Jonas Tegenfeldt.”
Han Cao is BioNano Genomics’ founder and chief scientific officer. Han Cao was a co-inventor of the technology while he was working as a postdoctoral researcher at Princeton University. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.
Fig.4: Bionano Genomics Founder and C.E.O posing next to Irys
Prior to that, Dr Cao was a postdoctoral fellow at the Institute for Human Gene Therapy of University of Pennsylvania Medical Center working on stem cell and DNA repair system projects. His diverse experience includes molecular biology, high throughput industrial microarray and genomics technology development, single-molecule analysis as well as micro and nanofluidics design and fabrication.
Dr. Cao received a B.S. degree from the University of Science and Technology of China and a Ph.D. in molecular biology from the University of Delaware. ~ VIB conferences
Erik Holmlin, Ph.D. is the current President & CEO of BioNano Genomics. 📷
Erik joined Bionano Genomics in January 2011. He has been leading the company ever since then. Over a decade ago.
According to his profile on bionanogenomics.com, Erik was a National Institutes of Health postdoctoral fellow at Harvard University and a National Science Foundation predoctoral fellow at the California Institute of Technology,
Pasadena (Caltech). He holds a Ph.D. in chemistry from Caltech and MBAs from UC Berkeley and Columbia University.
Christopher Stewart has been the CHIEF FINANCIAL OFFICER of Bionano Genomics since September 2020.
According to his profile on Bionano Genomics, Christopher Stewart is a seasoned leader with over 20 years of experience spanning finance, accounting, and strategic planning for many commercial-stage operating businesses.
Chris has served in a number of executive roles in both private and public companies as Controller, V.P. of Finance, and CFO.
He also has experience with major financing events, acquisitions, and scaling revenues in high-growth tech companies. He joined Bionano from Tesla, where he served as Head of the Maxwell Ultracapacitors business unit after Maxwell Technology was acquired by Tesla.
Chris received his Master of Science in Business Administration and Finance from the University of Southern California and his MBA in Finance from Carnegie Mellon University.
Mark Oldakowski has been the CHIEF OPERATING OFFICER of Bionano Genomics since October 2014.
According to his profile on Bionano Genomics, Mark has a 20-year history of success in the development of systems for the life sciences and medical device industries.
Prior to joining Bionano Genomics, Mark led a global team at Brooks Life Science Systems in the development of sample analyzers, high-throughput screening solutions, and chemical storage and biobank systems. Prior to his time at Brooks, Mark was with Affymetrix, where he launched the array platform that is widely used today for GWAS and other genomics applications.
Mark also spent time at Siemens Healthcare Diagnostics on the development of equipment for diagnostic core labs. During his 13 years at Life Technologies (formerly Applied Biosystems), he held various levels of responsibility in the development of systems for real-time PCR, sequencing, and sample preparation. Mark holds a bachelor’s degree in electrical engineering and a master’s degree in computer and systems engineering from Rensselaer Polytechnic Institute in New York.
Ph.D., FACMG has been the CHIEF MEDICAL OFFICER
Alka Chaubey is double board-certified in clinical cytogenetics/genomics and clinical molecular genetics/genomics by the American Board of Medical Genetics and Genomics (ABMGG).
According to her profile on the Bionano Genomics website, Previously, she was the Head of Cytogenomics at PerkinElmer Genomics, where Dr. Chaubey led the successful development and launch of several innovative products including the CNGnome test (low-pass whole genome sequencing), and a new FSHD assay utilizing Saphyr. She has also played an integral role on the Vanadis team at PerkinElmer in their efforts to bring a new PCR-free NIPT technology to the market. Prior to PerkinElmer Genomics, Dr. Chaubey was the Director of the Cytogenetics Laboratory at the Greenwood Genetic Center, SC, USA. She also holds an academic appointment as the Scientific Director of the Georgia Esoteric and Molecular Laboratory, Scientific Director of the Cytogenetics Laboratory of the Augusta University Medical Center, and Adjunct Assistant professor of Pathology of the Medical College of Georgia at Augusta University.
Dr. Chaubey serves on the Board of Directors for the Cancer Genomics Consortium and is also the Genetics Subdivision Nominating Committee representative of the Association of Molecular Pathologists (AMP). She originally received her Doctorate degree (PhD) from Guru Nanak Dev University, Amritsar, India and completed her post-doctoral studies at Center for Cellular and Molecular Biology (CCMB), Hyderabad, India**,** and University of Illinois at Chicago (UIC).
David L. Barker, PhD has been the CHAIRMAN of the Board Of Directors at Bionano Genomics since May 2010.📷
According to his profile on Bionano Genomics, Dr. David L. Barker, PhD, has served on our Board of Directors since May 2010, and as Chairman of our Board of Directors since August 2016. Dr. Barker also serves as a director of AmideBio, Singular Genomics Systems, and Aspen Neuroscience.
He is also a scientific advisor to MiNDERA Corp. and Luna DNA. He served as Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board until May 2016.
He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., acquired by Bio-Techne in 2016, IntegenX, acquired by Thermo Fisher Scientific in 2018, and Integrated Diagnostics, acquired by Biodesix in 2018.
Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations.
Bionano Genomics offers:
- Nanochannel Chips
- Automated Imaging Instruments
- Integrated Primary & Secondary Software
- Application-Specific Reagents.
Optical genome mapping (OGM) provides a direct, high-resolution view of intact, long DNA molecules free from the bias and errors introduced by Next-Generation Sequencing.
According to Bionano Genomics, FDA approval is not relevant at the moment. Saphyr and Irys are being used by researchers and clinicians without FDA approval.
The lack of FDA approval bars Bionano Genomics’ Saphyr and Irys from essential customers in the diagnostic arena, such as hospitals and clinical labs but It can still be called 'research use only' and be used for diagnostics services in laboratories.
Please see the Google Doc for more details.
Jump To The Original Source